CVRx, Inc. 8-K

What Happened

• On April 13, 2026 CVRx, Inc. filed an 8‑K and issued a press release announcing preliminary, unaudited financial results for the quarter ended March 31, 2026. The Company expects Q1 2026 revenue of $14.7–$14.8 million vs. $12.3 million in Q1 2025 (≈20% growth). Gross margin is expected to be ~87% (vs. 84% in Q1 2025) and total operating expenses are expected to be ~ $25.0 million (vs. $23.7 million in Q1 2025). Cash and cash equivalents were approximately $72.3 million as of March 31, 2026. CVRx expects to release audited Q1 results in mid‑May.

Key Details

• Q1 2026 revenue: $14.7–$14.8M vs. $12.3M in Q1 2025 (~20% growth).
• Gross margin: ~87% (Q1 2025: 84%); Operating expenses: ~ $25.0M (Q1 2025: $23.7M).
• Cash & equivalents: ~$72.3M as of March 31, 2026.
• Commercial footprint: 257 U.S. active implanting centers (up from 252 on 12/31/25); 56 U.S. sales territories (up 3 in Q1).
• Reimbursement update: CPT codes for Barostim moved from Category III to Category I (effective Jan 1, 2026), reducing automatic denials; 30‑day Medicare Advantage prior authorization approval rates (managed in‑house) rose from 31% (2024) to 44% (2025) and ~50% for Jan–Feb 2026.
• BENEFIT‑HF trial: first site activated on March 31, 2026; enrollment expected to begin in Q2 2026. Company notes the trial could expand the indicated patient population for Barostim by ~3× if successful.

Why It Matters

• The preliminary quarterly results show revenue growth and improved gross margins, suggesting continued commercial momentum for Barostim. Expansion in implanting centers and sales territories and better prior authorization approval rates indicate potential easing of reimbursement barriers that have affected procedure uptake.
• The BENEFIT‑HF trial activation is a key clinical development: if the trial meets its goals (as the Company states), it could substantially expand the addressable market.
• These figures are preliminary and unaudited; final results and any adjustments will be reported in mid‑May. Investors should note the forward‑looking statements and risks disclosed by the Company.